Immunohistochemical and clinicopathological study of non-Hodgkin's lymphoma in Erbil, Kurdistan

Tara Sirwan Kami; Rafal Abdul Razaq Al-rawi; Maysoon Alhaideri --------

doi:10.15218/zjms.2014.0029

Authors

Tara Sirwan Kami Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Rafal Abdul Razaq Al-rawi Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Maysoon Alhaideri -------- Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2014.0029

Keywords:

Non-Hodgkin lymphoma, CD20 & CD3

Abstract

Background and objective: Non-Hodgkin lymphoma is a cancer of the lymphatic system. Types of non-Hodgkin lymphoma vary significantly in their severity from indolent to very aggressive. The aim of this study was to investigate the incidence, immunohistochemical expression, clinical and histopathological prognostic factors of patients with non-Hodgkin lymphoma. Methods: A total of 59 patients with non-Hodgkin lymphoma cases were reviewed and investigated at Razgary Teaching Hospital in Erbil city during the period from January, 2011 to January, 2013. Data of patients were tabulated and distributed according to their age, sex, site, immunohistochemical expression and WHO classification. Results: Age of non-Hodgkin lymphoma patients ranged from 2 to 88 years with a mean of 45 year. Around 49% of the patients were of age group over 50 years and 54.2% of patients were male. Immunohistochemical investigation indicated that 71.2% of non-Hodgkin lymphomas were of B cell type, the highest percentage (33.3%) of them was of diffuse large cell type. While the T cell type was found in 20.3%, the highest percentage (33.3%) of them was of Anaplastic lymphoma. CD20 and CD3 showed more consistent and strong expression for B and T cells non-Hodgkin lymphoma, respectively. Results showed high BCL2 expression. Nodal non-Hodgkin lymphoma account for 50.8% of the total cases. Conclusion: Most non-Hodgkin lymphomas were of B cell type and highest percentage is of diffuse large cell type. CD20 and CD3 were more reliable as an indicator of B and T cell lineage, respectively. Most non-Hodgkin lymphomas were of intermediate-high grade. Nodal site represent highest rate for primary non-Hodgkin lymphoma.

Metrics

Metrics Loading ...

References

Michael W, Brunilda N, Hansa B, et al. Health wise. Non Hodgkin's lymphoma – Overview; 2010. Available from: http://www.webmd.com/cancer/non-hodgkins-lymphoma/non-hodgkins-lymphoma-topic-overview.

Dorland's Electronic Medical Dictionary. W.B. Saunders Company. 29th Edition, Available from: http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split. 2007

Iraqi Cancer Registry Team. Results of Iraqi Cancer Registry. Ministry of Health; 2005.

Othman RT, Abdulljabar R, Saeed A, Kittani SS, Sulaiman HM, Mohammed SA, et al. Cancer Incidence Rates in the Kurdistan Region/Iraq from 2007-2009. Asian Pacific J Cancer Prev 2011; 12: 1261-4.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W et al. SEER Cancer Statistics Review, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2008/, posted to the SEER web site. 2011.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. GLOBOCAN 2008. Lyon: International Agency for Research on Cancer; 2010.

Burton C, Jack A, Adamson P, Roman E. Descriptive epidemiology. In: Magrath IT, editor. The Lymphoid Neoplasms. 3rd edition. London: Hodder Arnold; 2010. P. 47-58.

Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. Cancer 1995;75: 370-80.

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17(12):3835-49.

Working_Formulation. Available from: http://en.wikipedia.org/wiki/. 2013.

Talaulikar D, Dahlstrom J, Shadbolt B, Broomfield A, McDonald A. Role of Immunohistochemistry in Staging Diffuse Large B-cell Lymphoma (DLBCL). JHC 2008; 56(10): 893–900.

Mattoch IW, Fulton R, Kim Y, Hoppe R, Warnke RA, Sundram UN. Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells. Am J Clinical Pathol2009; 131: 810-9.

Jaffe ES, Harris, NL, Stein H Vardiman, JW. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press. World Health Organization Classification of Tumors; Vol 3. 2001.

Yaqo RT, Hughson MD, Sulayvani FK, Al-Allawi NA. Malignant lymphoma in northern Iraq: A retrospective analysis of 270 cases according to the World Health Organization classification. Indian Journal of Cancer. Hematological Malignancies 2011;48:4 446-51

Kalyan K, Basu D, Soundararaghavan, J. Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol 2006 ;49(2):203-7.

Jaffe ES, Harris NL, Stein H, Vardiman JS. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC press; 2001.

Abdel-Ghafar AA, El Din El Telbany MA, Mahmoud HM, El-Sakhawy YN . Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry. Hematol 2012; 2(4):1.

Higgins RA, Blankenship JE, Kinney MC. Application of Immunohistochemistry in the Diagnosis of Non-Hodgkin and Hodgkin Lymphoma. Archives of Pathology & Laboratory Medicine 2008; 132(3): 441-61.

Pilozzi E, Pulford K, Jones M, Muller-Hermelink HK, Falini B, Ralfkiaer E, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998; 186:140–3.